New strategies for the treatment of hyperkalemia

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are vital for managing cardiovascular diseases (CVD), including hypertension, diabetes, chronic kidney disease, and heart failure (HF).
• Hyperkalemia is a significant adverse event in patients using RAASi and MRAs, often leading to dose reduction or treatment discontinuation, thereby compromising patient outcomes.
• Suboptimal management of hyperkalemia can increase mortality and morbidity risks in vulnerable patient populations.

Purpose of the Study:

• To review emerging therapeutic options for managing hyperkalemia in patients with CVD.
• To summarize recent international guideline recommendations for the safe continuation of RAASi and MRA therapies.
• To provide clinicians with evidence-based strategies for optimizing hyperkalemia management in patients with cardiovascular and renal conditions.

Main Methods:

• Literature review of recent clinical trials and guidelines.
• Synthesis of data on novel hyperkalemia management agents.
• Analysis of current recommendations for RAASi and MRA therapy in the context of hyperkalemia.

Main Results:

• Several new potassium-binding agents offer promising alternatives for managing hyperkalemia.
• Recent guidelines emphasize proactive hyperkalemia management to allow sustained use of RAASi and MRAs.
• Effective hyperkalemia control can prevent treatment interruption, improving cardiovascular and renal outcomes.

Conclusions:

• New strategies for hyperkalemia management are essential for maintaining the benefits of RAASi and MRA therapy in CVD patients.
• Adherence to updated guidelines can facilitate the continued use of these critical medications.
• Proactive management of hyperkalemia is key to improving long-term outcomes in patients with cardiovascular and chronic kidney diseases.